The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new, “positive” data on social functioning and quality of life from the Phase 3 Subcutaneou ...

Phase 3 trial results show Teva's TEV-'749 improves social functioning in adults with schizophrenia without post-injection ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

Copyright 2024 The Associated Press. All Rights Reserved. This image provided by Bristol Myers Squibb in October 2024 shows the company’s drug Cobenfy, which the U ...

Sally Littlefield, 29, of Alameda, California, said what works for her is a monthly injection of a long-acting antipsychotic medication. Littlefield, who has schizophrenia and bipolar disorder ...